A prospective clinical study of neoantigen-loaded personalized dendritic cell vaccine in the treatment of spinal metastasis from hepatic carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042735

Enrollment

Unknown

Registered

2021-01-27

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal tumor,Hepatic carcinoma

Interventions

DC vaccine immunotherapy group:DC vaccine immunotherapy

Traditional treatment group:Best treatment(chemotherapy or targeted drug therapy)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The age was 18-70 years old; 2) Hepatic carcinoma spinal metastasis with obvious pain or spinal instability or spinal cord compression; 3) After standard chemotherapy or targeted drug therapy, the control of primary tumor is not ideal; 4) No severe cognitive impairment, no sensory aphasia, can understand the basic instructions; 5) No serious basic diseases such as cardiovascular and cerebrovascular diseases; 6) Voluntarily participated in the study and signed the informed consent; 7) The expected survival time was more than 6 months.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

Measure	Time frame
Overall survival;Progress-free survival;	—

Secondary

Measure	Time frame
safety;adverse event;life quality score;	—

Countries

China

Contacts

Public ContactJianru Xiao

Department of Orthopedic Oncology, Changzheng Hospital, Navy Medical University

jianruxiao83@163.com+86 13701785283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026